ImmunityBio’s (IBRX) Bladder Cancer sBLA Resubmission Tests The Depth Of Its Immuno‑Oncology Strategy

ImmunityBio (IBRX) has resubmitted its supplemental Biologics License Application (sBLA) for ANKTIVA plus BCG to treat BCG-unresponsive non-muscle invasive bladder cancer with papillary tumors. This resubmission includes updated long-term efficacy and safety data, which could broaden ANKTIVA’s market beyond its current use. While the company faces ongoing losses and funding needs, recent European approval and distribution partnerships are helping to build its commercial footprint.